522: Relationship of PSA Velocity and Gleason Score in the PLCO Cancer Screening Trial
Robert L. Grubb, Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Jerome Mabie(Information Management Services), Lawrence R. Ragard(Westat (United States)), E. David Crawford(University of Colorado Denver), Douglas J. Reding(Ascension), David L. Levin(University of California San Diego), Thomas L. Riley(Automation, Information, and Management Systems (United States)), Paul F. Pinsky(National Cancer Institute)
Cited by 3
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k